OMER News and Press, Omeros Corporation From 01/12/23

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary During its Q3 earnings call, Omeros reported on FDA's initial response to its CRL appeal, setting the stage for progress towards approval. Frustratingly, Omeros has not uttered a peep since its Q3 2022 earnings report. Omeros stock has responded with wild gyrations raising i...

Omeros Corporation (OMER) Q3 2022 Earnings Conference Call November 09, 2022 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi -...

Omeros press release ( NASDAQ: OMER ): Q3 GAAP EPS of -$0.28 beats by $0.28 . Earned royalties of $16.5 million on net sales of our former ophthalmology product OMIDRIA For further details see: Omeros GAAP EPS of -$0.28 beats by $0.28

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicatio...

Bank of America downgraded Omeros Corporation ( NASDAQ: OMER ) on Tuesday after the FDA denied its appeal related to the Complete response letter (CRL) issued for narsoplimab in thrombotic microangiopathy linked to hematopoietic stem cell transplant. The appeal was part of...

The US FDA has denied an appeal of a Complete Response Letter issued to Omeros ( NASDAQ: OMER ) over its Biologics License Application for narsoplimab. Shares are down 7% in premarket trading. The company's dispute resolution request had asked the agency to acc...

-- Decision Denies Omeros’ Appeal Requesting Immediate Labeling Discussions -- -- Decision Proposes a Path Forward Based on Historical Survival Data -- Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food ...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at...

Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December 10-13, 2022 in New Orle...